Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Pharma (IGC) over the last 11 years, with Q1 2025 value amounting to $152000.0.

  • Pharma's Asset Writedowns and Impairment rose 6888.89% to $152000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $368000.0, marking a year-over-year increase of 7037.04%. This contributed to the annual value of $152000.0 for FY2025, which is 9559.16% down from last year.
  • Pharma's Asset Writedowns and Impairment amounted to $152000.0 in Q1 2025, which was up 6888.89% from $90000.0 recorded in Q1 2024.
  • In the past 5 years, Pharma's Asset Writedowns and Impairment ranged from a high of $169000.0 in Q1 2021 and a low of $37000.0 during Q2 2021
  • In the last 4 years, Pharma's Asset Writedowns and Impairment had a median value of $126000.0 in 2023 and averaged $114800.0.
  • In the last 5 years, Pharma's Asset Writedowns and Impairment plummeted by 7838.87% in 2021 and then surged by 6888.89% in 2025.
  • Over the past 4 years, Pharma's Asset Writedowns and Impairment (Quarter) stood at $37000.0 in 2021, then skyrocketed by 240.54% to $126000.0 in 2023, then fell by 28.57% to $90000.0 in 2024, then surged by 68.89% to $152000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $152000.0 for Q1 2025, versus $90000.0 for Q1 2024 and $126000.0 for Q1 2023.